Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

Conditions:   NSCLC;   BRAF V600 Mutation;   MET Exon 14 Mutation Interventions:   Drug: Dabrafenib + Trametinib;   Drug: Capmatinib Sponsor:   Sun Yat-sen University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials